Source: Eur Respir J 2013; 42: 291-292
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Shashikant Srivastava, Carleton Sherman, Tawanda Gumbo. In vitro susceptibility testing and totally drug-resistant tuberculosis. Eur Respir J 2013; 42: 291-292

Member's Comments

No comment yet.

Related content which might interest you: Characteristics of drug susceptibility testing for bedaquline and clofazimine of 178 drug-resistant Mycobacterium tuberculosis isolates in Japan Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019 Comparative analysis of M. tuberculosis drug susceptibility tests results in new multidrug-resistant tuberculosis cases and their confirmed contacts. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 In vitro susceptibility testing of bedaquiline against mycobacteria avium-intracellulare complex Source: Virtual Congress 2020 – Aspergillosis and chronic lung infections Year: 2020 The peculiarities of drug susceptibility of M. tuberculosis isolated from patients with late-stage HIV infection Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Detection of isoniazid or rifampin resistant Mycobacterium tuberculosis in patients with cavity and previously treated for tuberculosis - usefulness of rapid drug susceptibility test with sputum samples by reverse hybridization assay Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005 Improved tracking of nosocomial transmission of multidrug resistant M. tuberculosis with a novel T cell-based test Source: Eur Respir J 2003; 22: Suppl. 45, 167s Year: 2003 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 Susceptibility of Mycobacterium tuberculosis strains to fluoquinolones, obtained from chronic patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 315s Year: 2001 Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007 A new era for treatment of drug-resistant tuberculosis Source: Eur Respir J, 52 (4) 1801350; 10.1183/13993003.01350-2018 Year: 2018 In vitro susceptibility of non-tuberculous mycobacterial strains against moxifloxacin Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools Year: 2012 Induction of M. tuberculosis (MTB) drug resistance (DR) mutations in HIV-infected hosts and pathways of further spread of the evolutionary successful drug-resistant MTB clonal lines Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Method of treatment of destructive tuberculosis of single lung with extensively drug resistant mycobacteria tuberculosis Source: Annual Congress 2011 - Extrapulmonary tuberculosis and surgical interventions Year: 2011 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Transmission of multidrug-resistant and extensively drug-resistant tuberculosis in a metropolitan city Source: Eur Respir J 2013; 41: 901-908 Year: 2013 Treatment of drug-susceptible and drug-resistant tuberculosis Source: Eur Respir Monogr 2018; 82: 152-178 Year: 2018 The WHO strategy for TB control and elimination Source: Eur Respir Mon 2012; 58: 242-253 Year: 2012 Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019 Year: 2020 The effects of drug resistance phenotype on proliferation of Mycobacterium tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004 Laboratory system to detect multidrug-resistant (MDR) and extensively drug-resistant (XDR) mycobacterium tuberculosis strains in clinical practice Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008